Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
[...]after anti-TNF infusion tissue TNF is reduced as it passes into the blood bound to the anti-TNF antibody. Experimental studies suggest that if the duration of inflammation is limited, with its associated collateral lung damage, then bacterial superinfection is reduced.23 There is concern that anti-TNF therapy might increase the risk of bacteri...
Alternative Titles
Full title
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7158940
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7158940
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(20)30858-8
